Phylos is developing in vitro RNA-protein fusion technology for the rapid identification, selection and engineering of proteins (including antibodies) with unique characteristics. As this technology does not require the use of classical antibodies Or their components, we will investigate the targeting Of small protein scaffolds that may be more suitable for pharmacological use. Further, as we are able to select rare proteins from very large libraries (>10(l4) members), we expect to select binders with a much higher affinity ie KD
